Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement

Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement

Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. These steps delay access and prevent health care providers from...

Full description

Bibliographic Details
Main Authors: Sandeep R. Sehdev, Nigel S. B. Rawson, Olexiy I. Aseyev, Catriona J. Buick, Marcus O. Butler, Scott Edwards, Sharlene Gill, Joanna M. Gotfrit, Cyrus C. Hsia, Rosalyn A. Juergens, Mita Manna, Joy S. McCarthy, Som D. Mukherjee, Stephanie L. Snow, Silvana Spadafora, David J. Stewart, Jason R. Wentzell, Ralph P. W. Wong, Pawel G. Zalewski
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Current Oncology
Subjects:
oncology drugs
health technology assessment
drug prices
drug access
Canada
Online Access:https://www.mdpi.com/1718-7729/31/4/136

Internet

https://www.mdpi.com/1718-7729/31/4/136

Similar Items